Management of Cancer-Associated Thrombosis: An Evolving Area
1
Institute of Cardiometabolism and Nutrition, INSERM UMRS_1166, GRC 27 GRECO, Sorbonne Université, F-75013 Paris, France
2
Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, F-75013 Paris, France
3
Hematology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA
4
Internal Medicine, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, F-75010 Paris, France
5
Institut Universitaire d’Hématologie, EA 3518, Université de Paris, F-75010 Paris, France
6
Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada
*
Authors to whom correspondence should be addressed.
Cancers 2020, 12(10), 2999; https://doi.org/10.3390/cancers12102999
Received: 9 October 2020
/
Accepted: 14 October 2020
/
Published: 16 October 2020
(This article belongs to the Special Issue Treatment of Cancer-Associated Thrombosis)
The management of cancer-associated thrombosis (CAT) is an evolving area. With the use of direct oral anticoagulants as a new option in the management of CAT, clinicians now face several choices for the individual cancer patient with venous thromboembolism. A personalized approach, matching the right drug to the right patient, based on drug properties, efficacy and safety, side effect profile of each drug, and patient values and preference, will probably supplant the one size fits all approach of use of only low-molecular-weight heparin in the near future. We herein present eight translational, clinical research, and review articles on recent advances in the management of CAT published in the Special Issue “Treatment for Cancer-Associated Thrombosis” of Cancers. For now, a multidisciplinary patient-centered approach involving a close cooperation between oncologists and other specialists is warranted to guide clinical decision making and optimize the treatment of VTE in cancer patient.
View Full-Text
Keywords:
venous thromboembolism; cancer; low-molecular weight heparin; direct oral anticoagulant; risk assessment model
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Frere, C.; Connors, J.M.; Farge, D. Management of Cancer-Associated Thrombosis: An Evolving Area. Cancers 2020, 12, 2999. https://doi.org/10.3390/cancers12102999
AMA Style
Frere C, Connors JM, Farge D. Management of Cancer-Associated Thrombosis: An Evolving Area. Cancers. 2020; 12(10):2999. https://doi.org/10.3390/cancers12102999
Chicago/Turabian StyleFrere, Corinne, Jean M. Connors, and Dominique Farge. 2020. "Management of Cancer-Associated Thrombosis: An Evolving Area" Cancers 12, no. 10: 2999. https://doi.org/10.3390/cancers12102999
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
